Table 2.

Univariate Analysis Estimating the Prognostic Factors for HCC

Variables	Univariate Analysis
	N	Median Survival Time (Months)	Pa	HR	95% CI	Pb
Gender
Male	348	15
Female	59	13	0.382	1.147	0.838–1.571	0.392
Age
≥60	171	14
<60	236	18	0.026	1.288	1.026–1.617	0.029
T stage
I	46	14
II	117	23
III	229	13
IV	15	10	<0.001	1.341	1.138–1.580	<0.001
N stage
0	294	16
I	113	12	0.015	1.346	1.054–1.719	0.017
M stage
0	364	16
I	43	10	0.016	1.508	1.071–2.123	0.019
BCLC staging
A	131	23
B	131	15
C	143	11
D	2	3	<0.001	1.320	1.151–1.514	<0.001
NLR
≥3.82	133	9
<3.82	274	19	<0.001	1.842	1.457–2.329	<0.001
PLR
≥140.00	98	8
<140.00	309	18	<0.001	1.677	1.302–2.161	<0.001
MLR
≥0.27	225	10
<0.27	182	21	<0.001	1.626	1.291–2.048	<0.001
LDH
≥199.00	247	10
<199.00	160	24	<0.001	1.980	1.554–2.523	<0.001
ALP
≥134.50	168	7
<134.50	239	21	<0.001	1.835	1.461–2.304	<0.001
CEA
≥7.93	35	5
<7.93	372	16	0.001	1.842	1.276–2.660	0.001
Hepatitis
Without hepatitis	181	16
Hepatitis B	209	15
Hepatitis C	6	8	0.794	0.972	0.782–1.208	0.798
Liver cirrhosis
No	183	16
Yes	209	15	0.388	0.905	0.719–1.140	0.397
Portal vein involvement
Yes	68	4
No	310	18	<0.001	2.142	1.607–2.857	<0.001
Surgical history
Yes	177	23
No	230	29	0.646	1.055	0.835–1.333	0.653
Interventional treatment
TACE	223	30
TAI	180	25
TAE	4	26	0.949	1.008	0.812–1.253	0.940
AFP
<400	241	31
≥400	152	17	<0.001	1.686	1.334–2.131	<0.001

Notes: P^a is the P value for Log Rank test, P^b is the P value for HR in the univariate analysis. P-values in bold were found to be significant.

Abbreviations: BCLC staging, Barcelona Clinic Liver Cancer staging; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; MLR, monocyte–lymphocyte ratio; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; AFP, α-fetoprotein; HR, hazard ratio; CI, confidential interval.